PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers

Linjie Luo, Khandan Keyomarsi

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Fingerprint

Dive into the research topics of 'PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers'. Together they form a unique fingerprint.

Medicine & Life Sciences